Incyte Corp. Company Profile (NASDAQ:INCY)

About Incyte Corp.

Incyte Corp. logoIncyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: INCY
  • CUSIP: 45337C10
Key Metrics:
  • Previous Close: $81.33
  • 50 Day Moving Average: $84.40
  • 200 Day Moving Average: $77.64
  • Trailing P/E Ratio: 221.01
  • Foreward P/E Ratio: 57.27
  • P/E Growth: 8.03
  • Market Cap: $15.29B
  • Outstanding Shares: 188,002,000
  • Beta: 0.76
Additional Links:
Companies Related to Incyte Corp.:

Analyst Ratings

Consensus Ratings for Incyte Corp. (NASDAQ:INCY) (?)
Ratings Breakdown: 1 Hold Rating, 19 Buy Ratings
Consensus Rating:Buy (Score: 2.95)
Consensus Price Target: $108.22 (33.07% upside)

Analysts' Ratings History for Incyte Corp. (NASDAQ:INCY)
DateFirmActionRatingPrice TargetDetails
8/16/2016Piper Jaffray Cos.Set Price TargetBuy$99.00 -> $102.00View Rating Details
8/10/2016Jefferies GroupReiterated RatingBuy$98.00View Rating Details
8/10/2016Barclays PLCBoost Price TargetOverweight$85.00 -> $100.00View Rating Details
8/10/2016Leerink SwannBoost Price TargetOutperform$85.00 -> $95.00View Rating Details
8/5/2016SunTrust Banks Inc.Initiated CoverageBuy$105.00View Rating Details
7/12/2016Royal Bank Of CanadaInitiated CoverageOutperform$105.00View Rating Details
6/29/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
6/15/2016JMP SecuritiesReiterated RatingOutperform$100.00View Rating Details
6/7/2016BMO Capital MarketsReiterated RatingBuy$91.00 -> $97.00View Rating Details
6/6/2016Brean CapitalReiterated RatingBuyView Rating Details
5/19/2016Morgan StanleyReiterated RatingBuyView Rating Details
5/10/2016Oppenheimer Holdings Inc.Reiterated RatingBuyView Rating Details
5/3/2016Cowen and CompanyReiterated RatingBuyView Rating Details
2/22/2016ArgusBoost Price TargetBuy$92.00 -> $135.00View Rating Details
1/31/2016Bank of America Corp.Reiterated RatingBuy$145.00 -> $87.00View Rating Details
1/28/2016JPMorgan Chase & Co.Reiterated RatingBuyView Rating Details
1/19/2016Credit Suisse Group AGInitiated CoverageOutperform$110.00View Rating Details
1/5/2016Raymond James Financial Inc.Initiated CoverageMarket PerformView Rating Details
11/19/2015UBS AGReiterated RatingBuy$130.00View Rating Details
10/6/2015NomuraBoost Price TargetBuy$126.00 -> $146.00View Rating Details
(Data available from 8/30/2014 forward)


Earnings History for Incyte Corp. (NASDAQ:INCY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.05)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.09)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3($0.06)$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214$0.05($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.17)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Incyte Corp. (NASDAQ:INCY)
Current Year EPS Consensus Estimate: $0.2 EPS
Next Year EPS Consensus Estimate: $1.42 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.02$0.34$0.14
Q2 20164($0.06)$0.03($0.02)
Q3 20164($0.10)$0.01($0.04)
Q4 20164($0.10)$0.02($0.05)
(Data provided by Zacks Investment Research)


Dividend History for Incyte Corp. (NASDAQ:INCY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Incyte Corp. (NASDAQ:INCY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.00View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.00View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.76View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.82View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.66View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.92View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.36View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.08View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.78View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.73View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.00View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.18View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.00View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.30View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.00View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.00View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.00View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Incyte Corp. (NASDAQ:INCY)
DateHeadline logoAccounts Payable For Incyte Corporation (NASDAQ:INCY) Is $40.724 (NASDAQ:INCY) - August 29 at 5:31 PM logoAccounts Payable For Incyte Corporation (NASDAQ:INCY) Is $40.724 (NASDAQ:INCY) - August 29 at 5:31 PM logoIncyte : Immunovaccine Announces Additional Positive Topline Results from Phase 1/1b Clinical Trial Program with DPX-Survivac in Ovarian Cancer (NASDAQ:INCY) - August 29 at 10:08 AM
News IconForbes Magazine Names Incyte to its List of Worlds Most Innovative Companies for Second Consecutive Year (NASDAQ:INCY) - August 25 at 10:40 AM logoForbes Magazine Names Incyte to its List of World’s Most Innovative Companies for Second Consecutive Year (NASDAQ:INCY) - August 25 at 10:40 AM
News IconIncyte Corporation (NASDAQ:INCY) from Biotechnology – Todays Top Gains (NASDAQ:INCY) - August 24 at 5:32 PM logoCall buyers betting on rebound in Incyte (NASDAQ:INCY) - August 24 at 5:32 PM logoBiotech Stocks Seesaw As M&A Hopes Meet New Pricing Fears (NASDAQ:INCY) - August 24 at 5:32 PM logo4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss (NASDAQ:INCY) - August 23 at 10:01 AM logoPfizer-Medivation Deal Reignites Biotech Buyout Speculation (NASDAQ:INCY) - August 22 at 5:42 PM
News IconBiotechnology: Incyte Corporation (NASDAQ:INCY) Position of the day (NASDAQ:INCY) - August 19 at 5:39 PM
News IconUpdate on Incyte Corporation (NASDAQ:INCY) for the day (NASDAQ:INCY) - August 18 at 5:40 PM logoINCYTE CORP Financials (NASDAQ:INCY) - August 18 at 5:40 PM
News IconTop Gainers of the Day: Incyte Corporation (NASDAQ:INCY) from Biotechnology (NASDAQ:INCY) - August 18 at 8:41 AM logoIncyte Corporation (NASDAQ:INCY) Reports Accounts Payable Of $40.724 (NASDAQ:INCY) - August 15 at 8:48 PM logoIncyte Corp. breached its 50 day moving average in a Bearish Manner : INCY-US : August 12, 2016 (NASDAQ:INCY) - August 12 at 8:47 AM
News IconBetter Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation - (NASDAQ:INCY) - August 11 at 5:52 PM logoBetter Buy: Inovio Pharmaceuticals, Inc. vs. Incyte Corporation (NASDAQ:INCY) - August 11 at 5:52 PM logoETF’s with exposure to Incyte Corp. : August 11, 2016 (NASDAQ:INCY) - August 11 at 5:52 PM logoHow Will Incyte (INCY) Stock React to Price Target Raise at Barclays? (NASDAQ:INCY) - August 11 at 8:42 AM
News IconStong Jakafi sales fuel Incyte's earnings (NASDAQ:INCY) - August 10 at 5:56 PM logoIncyte Corp. :INCY-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:INCY) - August 10 at 5:56 PM logo10-Q: INCYTE CORP (NASDAQ:INCY) - August 10 at 8:31 AM logoIncyte Corporation Q2 Earnings Climb 271% (NASDAQ:INCY) - August 10 at 8:31 AM logoIncyte Corporation: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs (NASDAQ:INCY) - August 10 at 8:31 AM logoEdited Transcript of INCY earnings conference call or presentation 9-Aug-16 2:00pm GMT (NASDAQ:INCY) - August 10 at 8:31 AM logoRepros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline (NASDAQ:INCY) - August 10 at 8:31 AM logoIncyte Corporation: Incyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs - The Wall Street Transcript (NASDAQ:INCY) - August 9 at 8:38 AM logoQ2 2016 Incyte Corp Earnings Release - 07:00 am ET (NASDAQ:INCY) - August 9 at 8:38 AM logoIncyte Reports 2016 Second-Quarter Financial Results and Updates Key Clinical Programs (NASDAQ:INCY) - August 9 at 8:38 AM logoINCYTE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:INCY) - August 9 at 8:38 AM logo10-Q: ARIAD PHARMACEUTICALS INC (NASDAQ:INCY) - August 8 at 5:49 PM
News IconIs Incyte Corporation (NASDAQ:INCY), a large market cap stock a smart buy? (NASDAQ:INCY) - August 8 at 5:49 PM
News IconLeading stocks in today’s market: Incyte Corporation (NASDAQ:INCY) (NASDAQ:INCY) - August 5 at 5:47 PM logoCoverage initiated on Incyte by SunTrust (NASDAQ:INCY) - August 5 at 5:47 PM logoMylan (MYL) Q2 Earnings: Will the Stock Disappoint? (NASDAQ:INCY) - August 5 at 5:47 PM logoInvestors Traded Stocks: Incyte Corporation (NASDAQ:INCY) , VIVUS, Inc. (NASDAQ:VVUS) - Street Updates (NASDAQ:INCY) - August 5 at 8:39 AM logoIncyte Corporation (NASDAQ:INCY) Mean Price Target At $93.9 - (NASDAQ:INCY) - August 4 at 5:56 PM logoKite (KITE) Q2 Earnings: What's In Store For The Stock? (NASDAQ:INCY) - August 4 at 8:40 AM logo4 Biotech Stocks Poised to Surprise This Earnings Season (NASDAQ:INCY) - August 3 at 5:58 PM
News IconHC Stocks in Drift: Incyte Corporation (NASDAQ:INCY), Grifols SA, Barcelona (NASDAQ:GRFS) - share market updates (press release) (NASDAQ:INCY) - August 3 at 8:52 AM logoIncyte Corporation (NASDAQ:INCY) Quarterly Accounts Payable At $31.899 Millions - (NASDAQ:INCY) - August 2 at 10:28 AM logoPDL BioPharma Inc.: PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals (NASDAQ:INCY) - August 1 at 5:32 PM logoPDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals (NASDAQ:INCY) - August 1 at 5:32 PM logoCould a Spin-off of its Hepatitis C Division be in Gilead's Future? (NASDAQ:INCY) - August 1 at 5:32 PM logoNasdaq 100 Movers: AKAM, AAPL (NASDAQ:INCY) - July 28 at 8:41 AM logoAriad Pharmaceuticals : Reports Second Quarter and First Half 2016 Financial Results (NASDAQ:INCY) - July 28 at 8:41 AM
News IconARIAD Reports Second Quarter and First Half 2016 Financial Results (NASDAQ:INCY) - July 28 at 8:41 AM logoThe New #38 Most Shorted Nasdaq 100 Component: Incyte (NASDAQ:INCY) - July 27 at 5:56 PM
News IconBiotech Takeover Talk (NASDAQ:INCY) - July 26 at 5:50 PM


Incyte Corp. (NASDAQ:INCY) Chart for Tuesday, August, 30, 2016

Last Updated on 8/30/2016 by Staff